Nexium Antitrust

DEFENDANT NAME: AstraZeneca and Ranbaxy Laboratories Ltd.
STOCK SYMBOL:
CASE NUMBER: 1:12-md-02409-WGY
CASE NAME:
COURT: U.S. District Court for the District of Massachusetts
STATUS: Active
CLASS PERIOD:
LEAD PLAINTIFF DEADLINE:
DATE FILED: 01/25/13
COURT LOCATION:

First Circuit Decision

The First Circuit upheld the verdict, noting that “[the] jury found . . . the plaintiffs had proved an antitrust violation in the form of a large and unjustified reverse payment from AstraZeneca to Ranbaxy.”

Hagens Berman Sobol Shapiro was appointed liaison and co-lead counsel in a challenge to a pay-for-delay deal for the billion dollar drug, Nexium. The case went to trial before the Honorable William G. Young in October 2014 – the first pay-for-delay antitrust case to be tried since the Supreme Court’s decision in F.T.C. v. Actavis, Inc., 570 U.S. 136 (2013). A jury rendered an arguably inconsistent verdict for defendant AstraZeneca. The First Circuit upheld the verdict on appeal.

The Court approved two partial settlements: first, between the Direct Purchaser Class and the Teva defendants; and second, between the Direct Purchaser Class and the Dr. Reddy’s defendants. The case is In re: Nexium (Esomeprazole) Antitrust Litigation, United States District Court for the District of Massachusetts, Civil Action No. 1:12-md-02409 (WGY). Copies are available from the links at right.


Hagens Berman purchases advertisements on search engines, social media sites and other websites. Transmission of the information contained or available through this website is not intended to create, and receipt does not constitute, an attorney-client relationship. If you seek legal advice or representation by Hagens Berman, you must first enter a formal agreement. All information contained in any transmission is confidential and Hagens Berman agrees to protect information against unauthorized use, publication or disclosure. This site is regulated by the Washington Rules of Professional Conduct.

Back to all cases

Case videos

Case Gallery

Case Timeline

11/21/16: First Circuit Decision

The First Circuit upheld the verdict, noting that “[the] jury found . . . the plaintiffs had proved an antitrust violation in the form of a large and unjustified reverse payment from AstraZeneca to Ranbaxy.”

09/29/15: Notices of Appeal Filed

The court denied the motions for new trial and injunction, noting in his 97-page opinion that, "I did not try this case very well ..." All plaintiffs have filed notices of appeal to the First Circuit.

04/07/15: Settlements Approved

The court has approved the settlements and motions for expenses from the bench, with written orders to follow.

Related News